Profile data is unavailable for this security.
About the company
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
- Revenue in USD (TTM)91.06m
- Net income in USD-503.14m
- Incorporated2010
- Employees487.00
- LocationSAGE Therapeutics Inc215 1st StCAMBRIDGE 02142-1213United StatesUSA
- Phone+1 (617) 299-8380
- Fax+1 (617) 299-8379
- Websitehttps://www.sagerx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 739.41m | 300.00 | -- | 2.07 | -- | 3.86 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
Nurix Therapeutics Inc | 80.89m | -144.73m | 754.94m | 284.00 | -- | 3.71 | -- | 9.33 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Y-mAbs Therapeutics Inc | 84.82m | -21.43m | 755.16m | 100.00 | -- | 7.46 | -- | 8.90 | -0.4909 | -0.4909 | 1.94 | 2.31 | 0.6299 | 1.93 | 4.85 | 848,190.00 | -15.91 | -44.23 | -19.40 | -50.45 | 86.60 | -- | -25.26 | -181.13 | 5.27 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Zentalis Pharmaceuticals Inc | 0.00 | -292.19m | 788.37m | 168.00 | -- | 1.80 | -- | -- | -4.56 | -4.56 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -50.65 | -47.40 | -57.28 | -54.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
SAGE Therapeutics Inc | 91.06m | -503.14m | 788.69m | 487.00 | -- | 1.12 | -- | 8.66 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Pliant Therapeutics Inc | 1.58m | -161.34m | 799.22m | 158.00 | -- | 1.68 | -- | 505.84 | -2.75 | -2.75 | 0.0269 | 7.90 | 0.0037 | -- | 1.59 | 10,000.00 | -37.40 | -33.24 | -39.82 | -35.39 | -- | -- | -10,211.14 | -360.29 | -- | -- | 0.0208 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
Nuvation Bio Inc | 0.00 | -75.80m | 806.68m | 51.00 | -- | 1.18 | -- | -- | -0.3463 | -0.3463 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -11.72 | -16.27 | -11.97 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
Tango Therapeutics Inc | 36.53m | -101.74m | 809.99m | 140.00 | -- | 3.06 | -- | 22.18 | -1.08 | -1.08 | 0.3865 | 2.48 | 0.0871 | -- | 36.53 | 260,907.10 | -24.25 | -- | -27.59 | -- | -- | -- | -278.54 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
SS Innovations International Inc | 5.88m | -20.94m | 810.94m | 239.00 | -- | 56.71 | -- | 137.92 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Evolus Inc | 202.09m | -61.69m | 811.37m | 273.00 | -- | -- | -- | 4.02 | -1.08 | -1.08 | 3.55 | -0.3578 | 1.10 | 4.12 | 7.63 | 740,238.10 | -33.62 | -40.92 | -45.33 | -59.74 | 69.54 | 65.43 | -30.52 | -80.46 | 2.10 | -3.47 | 1.21 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
Regenxbio Inc | 90.24m | -263.49m | 816.07m | 344.00 | -- | 2.35 | -- | 9.04 | -6.03 | -6.03 | 2.06 | 7.08 | 0.1283 | -- | 3.41 | 262,331.40 | -37.45 | -16.75 | -45.96 | -19.08 | 58.76 | 78.27 | -291.99 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
Longboard Pharmaceuticals Inc | 0.00 | -54.42m | 821.80m | 50.00 | -- | 13.67 | -- | -- | -2.39 | -2.39 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -89.72 | -- | -105.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
CARGO Therapeutics Inc | 0.00 | -98.15m | 825.17m | 116.00 | -- | 2.13 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
National Research Corporation | 148.58m | 30.96m | 834.79m | 435.00 | 27.85 | 17.30 | 22.64 | 5.62 | 1.26 | 1.26 | 6.02 | 2.02 | 1.18 | -- | 11.00 | 341,563.20 | 24.49 | 26.25 | 33.80 | 36.77 | 62.30 | 63.20 | 20.84 | 23.95 | -- | 1,929.64 | 0.4286 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
ALX Oncology Holdings Inc | 0.00 | -160.81m | 839.29m | 72.00 | -- | 4.38 | -- | -- | -3.74 | -3.74 | 0.00 | 3.80 | 0.00 | -- | -- | 0.00 | -58.58 | -34.34 | -66.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0592 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
Holder | Shares | % Held |
---|---|---|
Wellington Management Co. LLPas of 31 Dec 2023 | 6.06m | 10.09% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.48m | 9.12% |
RTW Investments LPas of 31 Dec 2023 | 5.20m | 8.65% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 5.17m | 8.60% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.99m | 6.64% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.92m | 6.52% |
Bellevue Asset Management AGas of 31 Dec 2023 | 3.51m | 5.85% |
Cowen & Co. LLCas of 31 Dec 2023 | 1.34m | 2.23% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.17m | 1.94% |
JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 1.07m | 1.79% |